住院姑息治疗对造血干细胞移植后6个月心理痛苦的影响:随机临床试验结果
该随机临床试验纳入160例接受自体或异基因造血干细胞移植的血液恶性肿瘤患者,比较住院姑息治疗整合移植治疗与单独移植治疗对移植后6个月心理结局的影响。结果显示,干预组抑郁症状和PTSD症状较对照组显著降低,但生活质量与焦虑无差异;移植期间症状负担和焦虑部分介导了干预对抑郁和PTSD的效果。
要点
- 住院姑息治疗整合移植治疗可改善移植后6个月抑郁症状和PTSD症状。
- 干预组与对照组在生活质量及焦虑方面无差异。
- 移植期间症状负担和焦虑部分介导了干预对抑郁和PTSD的效果。
核心结论
- 住院姑息治疗整合移植治疗可改善移植后6个月抑郁症状和PTSD症状。
- 移植期间症状负担和焦虑的降低部分解释了干预对这些结局的效果。
研究设计与样本
- 随机对照试验,纳入160例接受自体或异基因造血干细胞移植的血液恶性肿瘤患者,干预组81例,对照组79例。
- 于2014年8月至2016年1月入组,共筛查186例潜在合格患者,入组160例(86%)。
- 基线和移植后6个月评估情绪、PTSD症状和生活质量;移植期间使用Edmonton症状评估量表评估症状负担。
- 采用协方差分析控制基线值检验干预效果,并进行因果中介分析。
主要发现
- 移植后6个月,生活质量或焦虑方面无差异。
- 移植住院期间症状负担和焦虑部分介导了干预对移植后6个月抑郁和PTSD的效果。
临床怎么用
- 对于接受造血干细胞移植的血液恶性肿瘤患者,可考虑将住院姑息治疗整合到移植治疗中,以改善移植后6个月的抑郁和PTSD症状。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Inpatient palliative care integrated with transplant care improves patients' quality of life (QOL) and symptom burden during hematopoietic stem-cell transplant (HCT). We assessed patients' mood, post-traumatic stress disorder (PTSD) symptoms, and QOL 6 months post-transplant. Methods We randomly assigned 160 patients with hematologic malignancies who underwent autologous or allogeneic HCT to inpatient palliative care integrated with transplant care (n = 81) or transplant care alone (n = 79). At baseline and 6 months post-transplant, we assessed mood, PTSD symptoms, and QOL with the Hospital Anxiety and Depression Scale and Patient Health Questionnaire, PTSD checklist, and Functional Assessment of Cancer Therapy-Bone Marrow Transplant. To assess symptom burden during HCT, we used the Edmonton Symptom Assessment Scale. We used analysis of covariance while controlling for baseline values to examine intervention effects and conducted causal mediation analyses to examine whether symptom burden or mood during HCT mediated the effect of the intervention on 6-month outcomes. Results We enrolled 160 (86%) of 186 potentially eligible patients between August 2014 and January 2016. At 6 months post-transplant, intervention participants reported lower depression symptoms on the Hospital Anxiety and Depression Scale and Patient Health Questionnaire (adjusted mean difference, -1.21 [95% CI, -2.26 to -0.16; P = .024] and -1.63 [95% CI, -3.08 to -0.19; P = .027], respectively) and lower PTSD symptoms (adjusted mean difference, -4.02; 95% CI, -7.18 to -0.86; P = .013), but no difference in QOL or anxiety. Symptom burden and anxiety during HCT hospitalization partially mediated the effect of the intervention on depression and PTSD at 6 months post-transplant. Conclusion Inpatient palliative care integrated with transplant care leads to improvements in depression and PTSD symptoms at 6 months post-transplant. Reduction in symptom burden and anxiety during HCT partially accounts for the effect of the intervention on these outcomes.
引用
- El-Jawahri A, Traeger L, Greer JA, et al. Effect of Inpatient Palliative Care During Hematopoietic Stem-Cell Transplant on Psychological Distress 6 Months After Transplant: Results of a Randomized Clinical Trial. J Clin Oncol. 2017. PMID: 28926288. doi:10.1200/JCO.2017.73.2800
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。